176 related articles for article (PubMed ID: 36439517)
1. A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Chen Y; Zhao H; Luo J; Liao Y; Dan X; Hu G; Gu W
Front Oncol; 2022; 12():944511. PubMed ID: 36439517
[TBL] [Abstract][Full Text] [Related]
2. A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.
Li T; Zhang Y; Peng D; Mao X; Zhou X; Zhou J
J Immunother Cancer; 2019 Feb; 7(1):51. PubMed ID: 30791947
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
6. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Bennani NN; Kim HJ; Pederson LD; Atherton PJ; Micallef IN; Thanarajasingam G; Nowakowski GS; Witzig T; Feldman AL; Ansell SM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35750419
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma.
Irlé C; Weintraub J
Case Rep Hematol; 2016; 2016():8175957. PubMed ID: 27648317
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.
Liu S; Yuan Z; Zhang C; Fu W; Hou J
Oncol Lett; 2012 Aug; 4(2):262-264. PubMed ID: 22844366
[TBL] [Abstract][Full Text] [Related]
11. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
Shen QD; Wang L; Zhu HY; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
J Cancer; 2021; 12(1):163-169. PubMed ID: 33391412
[No Abstract] [Full Text] [Related]
13. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.
Braunstein Z; Ruiz M; Hanel W; Shindiapina P; Reneau JC; Brammer JE
J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743749
[TBL] [Abstract][Full Text] [Related]
17. Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.
Lyu C; Cui R; Wang J; Mou N; Jiang Y; Li W; Deng Q
Front Oncol; 2021; 11():706087. PubMed ID: 34395279
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
19. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
20. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
